White Ferula Mushroom

Metadata

Regulatory Status

Italy and Sicily

• Conservation status: Pleurotus nebrodensis is listed as Endangered (EN) on the IUCN Red List. In Sicily, it occurs exclusively within the Madonie Mountains Regional Park, where wild populations number fewer than 150 mature individuals across fewer than 10 subpopulations.
• Legal protection: Collection is forbidden in the Park’s A zone (strict nature reserve). Collection of immature individuals (under 3 cm diameter) is prohibited throughout the entire Park.
• Wild harvest: Despite legal protections, illegal collection driven by the mushroom’s exceptionally high market price remains the primary threat to wild populations. Fresh wild specimens command prices of 30-100 EUR/kg.
• Cultivation: A formal cultivation project was completed in Sicily in 2002, demonstrating that P. nebrodensis can be grown commercially in shaded tunnel systems at various altitudes, producing fruiting bodies with organoleptic properties equivalent to wild specimens.

European Union

• Biodiversity protection: Listed among the IUCN Top 50 species targeted for fungal conservation. The species represents one of the most important fungal conservation cases in Europe.
• Novel Food: No specific novel food authorization for P. nebrodensis extracts or supplements. The fruiting body as a food mushroom does not require novel food authorization where there is a history of consumption.
• Geographic range: Recently discovered in three localities on the Greek mainland, expanding the known range beyond Sicily. Area of occupancy for both Sicily and Greece is less than 500 km squared.

China

• Cultivation: P. nebrodensis (known as Bai Ling Gu) has been successfully cultivated commercially in China, where it is marketed as a premium edible mushroom. Chinese researchers have been active in studying its medicinal properties.
• Not pharmacopoeial: Not listed in the Chinese Pharmacopoeia.

United States

• Status: Not commercially available in the US market. No FDA GRAS determination. Not marketed as a dietary supplement. Available through specialty cultivation sources.

Conditions & Indications

Primary Indications (Preclinical Evidence)

• Immune modulation — Polysaccharides isolated from P. nebrodensis (PN-S) stimulated the production of nitric oxide (NO), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), and interferon-gamma (IFN-gamma) in RAW264.7 macrophages. PN-S also upregulated mRNA expression of IFN-gamma, IL-6, inducible nitric oxide synthase (iNOS), and TNF-alpha genes, demonstrating a robust innate immune activation profile.
• Antitumor activity — In vitro experiments have demonstrated the ability of P. nebrodensis extracts to specifically inhibit colon cancer cell proliferation by inducing apoptosis. Additionally, the unique protein nebrodeolysin showed strong cytotoxicity against multiple human cancer cell lines (L929 and HeLa), inducing apoptosis as evidenced by microscopic observations and DNA ladder formation.

Secondary Indications (Preclinical Evidence)

• Anti-HIV-1 activity — Nebrodeolysin demonstrated anti-HIV-1 activity in CEM cell culture, marking the first time a hemolytic protein from mushrooms was shown to possess antiviral activity against HIV-1. While the activity was modest compared to known lectins, the mechanism appears distinct, involving cell membrane interactions that suppress viral infection.
• Cardioprotection — A polysaccharide designated PNPA, isolated from P. nebrodensis, offered significant cardiac protection against ischemia-reperfusion injury in rats. The same polysaccharide also ameliorated hepatic ischemia-reperfusion injury in rat models.
• Antimicrobial and anti-biofilm activity — P. nebrodensis extract reduced biofilm formation by methicillin-resistant Staphylococcus aureus (MRSA) by up to 71% and Pseudomonas aeruginosa by 18% compared to untreated controls, suggesting potential application against antibiotic-resistant bacterial infections.

Emerging/Preclinical Indications

• Hepatoprotection — The PNPA polysaccharide ameliorated hepatic ischemia-reperfusion injury, suggesting hepatoprotective potential beyond the cardiac applications.
• Antioxidant activity — Like other Pleurotus species, P. nebrodensis contains phenolic compounds with free radical scavenging capacity, though species-specific antioxidant studies are limited.
• Hypocholesterolemic potential — As a Pleurotus species, P. nebrodensis likely contains lovastatin and ergosterol, though specific quantification studies for this species are limited.

Mechanism of Action

Primary Mechanisms

1. Polysaccharide-mediated macrophage activation PN-S polysaccharides from P. nebrodensis activate macrophages through stimulation of pattern recognition receptor signaling, leading to upregulated expression of inducible nitric oxide synthase (iNOS) and pro-inflammatory cytokines. The signaling cascade results in increased production of nitric oxide (NO), which serves as both an antimicrobial effector molecule and a signaling molecule in immune regulation, alongside IL-6, TNF-alpha, and IFN-gamma. Upregulation of IFN-gamma is particularly significant as it bridges innate and adaptive immunity by enhancing antigen presentation and promoting Th1 polarization.

2. Nebrodeolysin-mediated apoptosis induction Nebrodeolysin is a novel hemolytic protein unique to P. nebrodensis that interacts with cell membranes to form pores, leading to hemolysis in erythrocytes and apoptosis in tumor cell lines. The apoptosis-inducing mechanism is evidenced by characteristic DNA laddering and morphological changes consistent with programmed cell death. The protein’s dual functionality — apoptosis induction and anti-HIV-1 activity — suggests membrane interactions that may disrupt both cancer cell viability and viral entry mechanisms.

3. PNPA-mediated ischemia-reperfusion protection The PNPA polysaccharide provides cardio- and hepatoprotection during ischemia-reperfusion injury, likely through antioxidant mechanisms that reduce reactive oxygen species (ROS) generated during reperfusion, suppression of inflammatory cascades triggered by tissue ischemia, and potential modulation of apoptotic pathways in ischemia-damaged tissues.

Secondary Mechanisms

• Anti-biofilm activity: P. nebrodensis extracts interfere with bacterial quorum sensing or extracellular matrix formation, reducing the ability of MRSA and P. aeruginosa to form protective biofilm structures that confer antibiotic resistance.
• Apoptosis in colon cancer cells: Beyond nebrodeolysin-mediated effects, crude extracts of P. nebrodensis specifically induced apoptosis in colon cancer cell lines, suggesting additional bioactive components contribute to anticancer activity.

Key Active Compounds

Clinical Evidence Summary

No human clinical trials have been conducted with Pleurotus nebrodensis. All evidence derives from in vitro and animal studies.

Key Preclinical Studies

Evidence Limitations

• The total number of pharmacological studies on P. nebrodensis is small compared to more extensively studied Pleurotus species.
• No human clinical trials exist for any indication.
• Nebrodeolysin’s anti-HIV-1 activity was described as modest compared to known lectins, and the mechanism remains unclear.
• The conservation status of wild populations limits availability of research material, though cultivated specimens are increasingly available.
• Most immunomodulatory data comes from in vitro macrophage assays, which may not fully predict in vivo immune responses.
• Cardioprotective studies with PNPA are limited to ischemia-reperfusion models in rats.
• Dose-response relationships and pharmacokinetics have not been established.

Safety Profile

General Assessment

P. nebrodensis has been consumed as a prized culinary mushroom in Sicily for centuries and is considered safe as a food. The cultivated form retains the same characteristics as wild specimens. No adverse effects from dietary consumption have been reported. Safety data for concentrated extracts are limited to the preclinical studies described above.

Contraindications

• Known mushroom allergy: Individuals with allergies to Pleurotus species or other basidiomycete mushrooms should avoid P. nebrodensis.
• Pregnancy and lactation: Insufficient safety data. Culinary consumption is likely safe based on traditional use, but supplemental doses of extracts should be avoided.

Drug Interactions

• Theoretical — statins and lipid-lowering drugs: As a Pleurotus species likely containing lovastatin, additive effects with prescribed statin medications are theoretically possible. No clinical interaction data exist.
• Theoretical — immunosuppressants: Given the demonstrated macrophage-activating properties of PN-S polysaccharides, concurrent use with immunosuppressive drugs could theoretically reduce their efficacy. No clinical data exist.
• Theoretical — anticoagulants: No specific anticoagulant interactions have been documented, but general caution is warranted with concentrated mushroom extracts in patients on anticoagulant therapy.

Side Effects

• From food consumption: No adverse effects documented from culinary use.
• From extracts: No adverse effects reported in preclinical studies at tested doses.
• General: As with other Pleurotus species, mild gastrointestinal discomfort is possible with high intake.

Clinical Dosage

As Culinary Food

• Fresh fruiting body: No therapeutic dose established. Consumed as a premium culinary ingredient in Italian and Chinese cuisine. The mushroom is prized for its delicate flavor, firm white flesh, and excellent texture.
• Note: Wild specimens from Sicily are extremely expensive (30-100 EUR/kg) and legally restricted in collection. Cultivated specimens offer a sustainable and more affordable alternative.

No Established Therapeutic Doses

• No human therapeutic doses have been established for any P. nebrodensis preparation.
• Preclinical studies have used various concentrations of polysaccharide fractions and protein isolates, but these have not been translated to human dosing.
• Given the lack of clinical data, no specific supplementation recommendations can be made.

Conservation Note

• Any commercial development of P. nebrodensis for medicinal purposes should be based exclusively on cultivated material to protect remaining wild populations.
• The 2002 Sicilian cultivation project demonstrated that commercial production is viable and can produce mushrooms with properties equivalent to wild specimens.
• Ex situ cultivation may also serve conservation goals by reducing economic incentives for illegal wild harvest.

Sources

• Lv H, Kong Y, Yao Q, et al. Nebrodeolysin, a novel hemolytic protein from mushroom Pleurotus nebrodensis with apoptosis-inducing and anti-HIV-1 effects. Phytomedicine. 2009;16(2-3):198-205
• Lv H, et al. Polysaccharide extracted from Pleurotus nebrodensis increased the production of nitric oxide, IL-6, TNF-alpha, and IFN-gamma in macrophages. Immunopharmacol Immunotoxicol. 2009;31(4):612-617
• Chen J, et al. A polysaccharide (PNPA) from Pleurotus nebrodensis offers cardiac protection against ischemia-reperfusion injury in rats. Carbohydr Polym. 2012;87(2):1597-1604
• Ferrante P, et al. Potential activity of Pleurotus nebrodensis mushroom extract against biofilm of meticillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa. Front Bacteriol. 2025;4:1697820
• Ferroni C, et al. Pleurotus nebrodensis (Basidiomycota), a rare endemic mushroom of Sicily: current and future issues. Ital Bot. 2024;17:41-58
• IUCN. Pleurotus nebrodensis. The IUCN Red List of Threatened Species. Species ID 39. Available at: https://top50.iucn-mpsg.org/species/39
• Ferroni C, et al. Conservation Strategies of the Culinary-Medicinal Mushroom Pleurotus nebrodensis (Basidiomycota, Fungi). Conservation. 2024;15(1):14
• Venturella G, Ferraro V, Cirlincione F, Ferroni C. Pleurotus nebrodensis: A Very Special Mushroom. Bentham Science Publishers, 2014
• Zervakis GI, et al. Pleurotus eryngii and P. nebrodensis: from the wild to commercial production. Mushroom Science. 2004;16:467-474

Connections

• Oyster Mushroom — The common oyster mushroom (Pleurotus ostreatus) is the most widely studied member of the genus and provides the baseline for understanding Pleurotus pharmacology, including beta-glucan immunomodulation, lovastatin content, and antioxidant properties. P. nebrodensis shares the genus but has unique compounds like nebrodeolysin.
• King Trumpet — The closest relative to P. nebrodensis. Both are members of the “eryngii species complex” associated with Apiaceae host plants. P. eryngii is widely cultivated and commercially successful, providing a template for P. nebrodensis cultivation development.
• Lung Oyster — Another Pleurotus species with documented immunomodulatory polysaccharides, useful as a pharmacological comparator.
• Golden Oyster — A Pleurotus species with antitumor polysaccharides, demonstrating that immunomodulatory activity is a genus-wide characteristic.
• Turkey Tail — Contains the most clinically validated mushroom polysaccharides (PSK/PSP) for cancer adjunctive therapy, representing the endpoint of a development pathway that P. nebrodensis polysaccharides might follow.
• Reishi — The most thoroughly studied immunomodulatory mushroom, providing context for understanding the significance of P. nebrodensis macrophage activation data.